Literature DB >> 27486587

A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient.

Aleksandra Mamorska-Dyga1, Faisal M H Ronny1, Carmelo Puccio1, Humayun Islam1, Delong Liu1.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, with about 30% of new cases presenting with extranodal disease. Lesions originating from soft tissues of the upper extremities are extremely rare and may mimic other malignancies like sarcoma. We present a case of an elderly patient with right upper extremity (RUE) mass which was proven to be DLBCL instead of sarcoma. We emphasize the increasing need for investigating new therapeutic options for patients of extreme age and/or with underlying heart disease.

Entities:  

Keywords:  Diffuse large B-cell lymphoma (DLBCL); right upper extremity (RUE); targeted agents

Year:  2016        PMID： 27486587      PMCID： PMC4958056          DOI： 10.21037/sci.2016.06.06

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN： 2306-9759


  34 in total

1.  Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.

Authors:  Rachel B Salit; Daniel H Fowler; Wyndham H Wilson; Robert M Dean; Steven Z Pavletic; Kieron Dunleavy; Frances Hakim; Terry J Fry; Seth M Steinberg; Thomas E Hughes; Jeanne Odom; Kelly Bryant; Ronald E Gress; Michael R Bishop
Journal:  J Clin Oncol       Date:  2012-02-06       Impact factor: 44.544

2.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

Authors:  S M Swain; F S Whaley; M C Gerber; S Weisberg; M York; D Spicer; S E Jones; S Wadler; A Desai; C Vogel; J Speyer; A Mittelman; S Reddy; K Pendergrass; E Velez-Garcia; M S Ewer; J R Bianchine; R A Gams
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

3.  Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.

Authors:  Sarah Rohlfing; Matthias Aurich; Tilman Schöning; Anthony D Ho; Mathias Witzens-Harig
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-03-24

4.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

5.  Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study.

Authors:  Rodrigo Martino; Granada Perea; María Dolores Caballero; María V Mateos; Josep M Ribera; Jaime Pérez de Oteyza; Reyes Arranz; María José Terol; Jorge Sierra; Jesús F San Miguel
Journal:  Haematologica       Date:  2002-08       Impact factor: 9.941

6.  Lymphoma in soft tissue: a clinicopathologic study of 19 cases.

Authors:  D R Salamao; A G Nascimento; R V Lloyd; M G Chen; T M Habermann; J G Strickler
Journal:  Hum Pathol       Date:  1996-03       Impact factor: 3.466

Review 7.  Ibrutinib and novel BTK inhibitors in clinical development.

Authors:  Akintunde Akinleye; Yamei Chen; Nikhil Mukhi; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-08-19       Impact factor: 17.388

8.  Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis.

Authors:  Shamudheen M Rafiyath; Mohammad Rasul; Byung Lee; Guoqing Wei; Gurpreet Lamba; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2012-04-23

Review 9.  Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.

Authors:  Jingjing Wu; Jiaping Fu; Mingzhi Zhang; Delong Liu
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388

10.  Ibrutinib for B cell malignancies.

Authors:  Aileen Novero; Pavan M Ravella; Yamei Chen; George Dous; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2014-01-28
View more
  2 in total

1.  Diffuse Large B-Cell Lymphoma of the Left Upper Extremity Mimicking a Sarcoma.

Authors:  Raheel S Siddiqui; Debra Ferman; Sandeep Tuli; M Margaret Kemeny
Journal:  Cureus       Date:  2021-06-11

Review 2.  Diagnosis and treatment of CD20 negative B cell lymphomas.

Authors:  Tasleem Katchi; Delong Liu
Journal:  Biomark Res       Date:  2017-02-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.